Bert M. Glaser
About
In The Last Decade
Bert M. Glaser
124 papers receiving 6.2k citations
Peers
Comparison fields: 5 of 128
- Ophthalmology 4.8k
- Radiology, Nuclear Medicine and Imaging 4.4k
- Molecular Biology 1.6k
- Neurology 1.4k
- Immunology and Allergy 347
Countries citing papers authored by Bert M. Glaser
This map shows the geographic impact of Bert M. Glaser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert M. Glaser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert M. Glaser more than expected).
Fields of papers citing papers by Bert M. Glaser
This network shows the impact of papers produced by Bert M. Glaser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert M. Glaser. The network helps show where Bert M. Glaser may publish in the future.
Co-authorship network of co-authors of Bert M. Glaser
This figure shows the co-authorship network connecting the top 25 collaborators of Bert M. Glaser. A scholar is included among the top collaborators of Bert M. Glaser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bert M. Glaser. Bert M. Glaser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Pretreatment levels of vitreous protein biomarkers correlate with visual acuity outcome in response to intravitreal triamcinolone in Diabetic Macular Edema | 1 |
| 2 | Vitreous Proteomics Demonstrates That TGFβ and TGFβR Parallel Severity of Diabetic Macular Edema | 1 |
| 3 | Vitreous Levels of TNFαR are Inversely Related to Severity of Diabetic Macular Edema | 1 |
| 4 | The Difference in Response After 3 months of Anti-VEGF in wet AMD Correlates with Differences in Vitreous Protein Biomarkers | 1 |
| 5 | Long-Term Differences in the Vitreous Proteome of wet AMD Anti-VEGF Responders versus Non-Responders During 12 months of Treatment. | 1 |
| 6 | Changes in the Vitreous Proteome One Month Following Initial Anti-VEGF Treatment for Wet AMD Correlate with Treatment Response | 1 |
| 7 | Sequential in-office Vitreous aspirations demonstrate that up-regulation of Matrix Metalloproteinases may regulate angiogenesis in Diabetic Retinopathy | 1 |
| 8 | Sequential In-Office Vitreous Aspirates Demonstrate That MMP-9 Levels Correlate With and Predict the Progression of SRF in Eyes With Wet AMD | 1 |
| 9 | Feeder vessel treatment of occult with no classic choroidal neovascularization in age-related macular degeneration | 1 |
| 10 | 46 | |
| 11 | 20 | |
| 12 | 46 | |
| 13 | 33 | |
| 14 | 50 | |
| 15 | 173 | |
| 16 | 33 | |
| 17 | Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. | 42 |
| 18 | 16 | |
| 19 | 1 | |
| 20 | Supplemented fasting in preparation for surgical treatment. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.